Pravastatin Reduces the Risk of Atherothrombotic Stroke when Administered within Six Months of an Initial Stroke Event.

ABSTRACT:

Aims

The J-STARS study examined whether pravastatin (10 mg/day) reduces recurrence of stroke in non-cardioembolic ischemic stroke patients who were enrolled within 1 month to 3 years after initial stroke events (ClinicalTrials.gov, NCT00221104). The main results showed that the frequency of atherothrombotic stroke was low in pravastatin-treated patients, although no effect of pravastatin was found for the other stroke subtypes. We evaluated differences of early (within 6 months) or late (after 6 months) pravastatin treatment benefits on the incidence of stroke or transient ischemic attack (TIA), as well as atherothrombotic stroke and the other subtypes.

Methods

Subjects in the J-STARS study were classified into two cohorts, depending on whether they enrolled early (1 to 6 mo

SUBMITTER: Hosomi N 

PROVIDER: S-EPMC5868512 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature